Prelude Therapeutics (PRLD) Other financing activities (2020 - 2026)

Prelude Therapeutics (PRLD) has 7 years of Other financing activities data on file, last reported at $31000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $31000.0; the trailing twelve-month figure through Mar 2026 stood at $181000.0 (down 51.99% YoY), and the FY2025 full-year result was $150000.0, down 60.42% from the prior year.
• Other financing activities fell to $31000.0 in Q1 2026, from $58000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $320000.0 in Q2 2023 to a low of -$317000.0 in Q3 2023.
• A 5-year average of $68866.7 and a median of $59000.0 in 2022 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities slumped 460.23% in 2023 and soared 1893.75% in 2024, its largest moves.
• Tracing PRLD's Other financing activities over 5 years: stood at $126000.0 in 2022, then plunged by 87.3% to $16000.0 in 2023, then soared by 1893.75% to $319000.0 in 2024, then tumbled by 81.82% to $58000.0 in 2025, then sank by 46.55% to $31000.0 in 2026.
• Business Quant data shows PRLD's Other financing activities at $31000.0 in Q1 2026, $58000.0 in Q4 2025, and $92000.0 in Q3 2025.